Please assess the completion status of the following clinical trial:

Trial Title: Effect of IMN1207 Versus Casein on Weight Loss, Survival and Quality of Life in Non-small Cell Lung Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Non small cell lung cancer stage III or stage IV.~* Karnofsky performance status greater or equal to 70%.~* Expected participation in study for more than 3 months.~* Involuntary decrease in body weight of more than 3% over the 1-5 months period immediately preceding study entry.~* Age 18 or older.~* Serum creatine less or equal to 3.0mg/dL or 265 µmol/L.~* Total bilirubin in the normal range (0.2-1.2 mg/dL) SGPT equal to or less than 4 times the upper limit of normal.~* Reliable contraception (ovariectomy, hysterectomy, tubuligation for at least six months, oral contraceptive, barrier method, etc.) for women of child bearing potential.~Exclusion Criteria:~* History of angioedema or allergic reactions to any compound employed in this study.~* Pregnancy and lactating.~* Uncontrolled metastatic brain tumors.~* Milk protein intolerance.~* Subjects currently using N-acetylcysteine, alpha-lipoic acid supplements, or dry whey protein supplements.~* Presence of ascitis or edema according to principle investigator's clinical judgment.~* Significant anemia, as defined by the requirement of treatment with EPO.~* Subjects with either mild or soy allergy/intolerance.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IMN1207 (Type: EXPERIMENTAL): Dietary Supplement: IMN1207~Stratum A: CRP \<40 mg/L and WBC \< 11x109/L (i.e. subjects with relatively low levels of inflammation).~Stratum B: CRP ≥ 40 mg/L and/or WBC ≥ 11x109/L (i.e. subjects with relatively high levels of inflammation.
- Casein (Type: PLACEBO_COMPARATOR): Dietary Supplement: Casein.~Stratum A: CRP \<40 mg/L and WBC \< 11x109/L (i.e. subjects with relatively low levels of inflammation).~Stratum B: CRP ≥ 40 mg/L and/or WBC ≥ 11x109/L (i.e. subjects with relatively high levels of inflammation.

Based on this trial design, predict the completion outcome and termination type (if applicable).